EP
IMVT icon

Eversept Partners’s Immunovant IMVT Stock Holding History

Eversept Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-92,909
Closed -$2.45M – 72
2024
Q2 		$2.45M Sell
92,909
-162,617
-64% -$4.63M 0.17% 62
2024
Q1 		$8.26M Buy
255,526
+141,733
+125% +$5.17M 0.55% 33
2023
Q4 		$4.79M Buy
+113,793
New +$4.19M 0.42% 39
2021
Q3 		– Sell
-110,183
Closed -$1.16M – 113
2021
Q2 		$1.16M Sell
110,183
-120,000
-52% -$1.68M 0.08% 76
2021
Q1 		$3.69M Buy
+230,183
New +$6.07M 0.28% 52
2020
Q3 		– Sell
-12,266
Closed -$299K – 59
2020
Q2 		$299K Sell
12,266
-64,600
-84% -$1.38M 0.04% 68
2020
Q1 		$1.2M Hold
76,866
– – 0.3% 38
2019
Q4 		$1.22M Buy
+76,866
New +$861K 0.22% 61

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Eversept Partners's IMVT Position: Q3 2024 in Review

Eversept Partners sold out of Immunovant (IMVT) in Q3 2024, closing a stake of 92,909 shares — an estimated $2.45M sold.

Eversept Partners first reported a position in IMVT in Q4 2019 and held it in 8 quarters. The position peaked at $8.26M in Q1 2024. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2024.

  • Eversept Partners reported no remaining Immunovant position as of Q3 2024 after selling out during the quarter.
  • Eversept Partners sold 92,909 Immunovant shares in Q3 2024, an estimated $2.45M.
  • Eversept Partners first reported a position in Immunovant in Q4 2019 and held it in 8 quarters.
  • Eversept Partners's Immunovant position peaked at $8.26M in Q1 2024.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2024.

Based on Eversept Partners's 13F filing for Q3 2024, filed 14 Nov 2024.